Citi analyst Yigal Nochomovitz lowered the firm’s price target on ProQR Therapeutics to $2.25 from $3 and keeps a Neutral rating on the shares. The analyst cites dilution related to the expanded agreement with Lilly announced in December 2022 for the target drop.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PRQR:
- ProQR Therapeutics management to meet with Cantor Fitzerald
- ProQR Therapeutics price target raised to $5 from $1.50 at H.C. Wainwright
- ProQR Therapeutics upgraded to Outperform from Market Perform at JMP Securities
- ProQR announces initial pipeline targets, highlights Axiomer platfotform
- ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event